HOME : Support : Dialog Search Aids : Bluesheets
RSS FeedAdd RSS | What is RSS?
View Bluesheets by | Database Name | File Number | Subject | OneSearch Categories | Search Options |
70
SEDBASE: Side Effects of Drugs

Last Loaded on Web: Tuesday, July 01, 2008

Last Update To Bluesheet: August 3, 2006

Bluesheet Contents     PDF version

File Description Dialog File Data Special Features Sample Record Sort Rates
Subject Coverage Database Content DIALINDEX/OneSearch Categories Basic Index Rank
Sources Document Types Indexed Contact Additional Indexes Map
Print Counterparts Geographic Coverage Terms and Conditions Limit Predefined Format Options


File Description [top]

SEDBASE: Side Effects of Drugs is a fulltext database that critically analyzes the published drug side effect literature on drugs currently in use. SEDBASE: Side Effects of Drugs acts as a quality filter since its drug class chapters are prepared by recognized authorities who critically assess and distill the published journal literature each year. The goal of the database is to document every drug known to have a side effect reported in the literature.

SEDBASE: Side Effects of Drugs is organized by drug class chapters and does not contain any speculative or unsubstantiated statements. Each year approximately 9,000 articles on adverse drug reactions are published in the scientific literature. These articles are sent to recognized authorities who critically assess the information and distill the key elements for inclusion in the database. Some of the specific areas covered include: adverse drug reactions, drug interactions, drug toxicity, special risk situations, and pharmacological or patient-dependent factors associated with the occurrence of side effects.



Subject Coverage [top]

  • Adverse Drug Reactions
  • Drug Interactions
  • Drug Toxicity
  • Pharmacological or Patient-Dependent Factors Associated with the Occurrence of Side Effects
  • Special Risk Situations


Sources [top]

SEDBASE contains current, full-text information from the last 12 years of Meyler's Side Effects of Drugs, published every 4 years; Side Effects of Drugs Annual, published every year in between; and Marler's Pharmacological & Chemical Synonyms. SEDBASE also contains citations and abstracts from EMBASE (Files 72, 73) that have been referenced by the Meyler's texts.



Print Counterparts [top]

  • Meyler's Side Effects of Drugs; Side Effects of Drugs Annual; Marler's Pharmacological & Chemical Synonyms


Dialog File Data [top]

Dates Covered: 1996-1997
File Size: 85,777 records as of December 1997
Update Frequency: Closed


Database Content [top]

  • Complete Text Records


Document Types Indexed [top]

  • NA


Geographic Coverage [top]

  • International


Geographic Restrictions [top]

  • None


Special Features [top]

  • ERA Available
  • Graduate Education Program
  • KWIC and HILIGHT Available
  • Abstracts Available for some cited references
  • MAP Available


DialIndex/OneSearch Categories [top]

ACRONYM CATEGORY NAME
PHARMR Pharmacology + RINGDOC-Files
SAFETY Safety
TOXICOL Toxicology


Contact [top]

SEDBASE is produced by Elsevier. Questions concerning file content should be directed to:

Elsevier B.V.
P.O. Box 211
Amsterdam, 1000 AE
The Netherlands
Telephone: +31-20-4853-507
Fax: +31-20-4853-432
E-Mail: ebd-marketing@elsevier.com


Terms and Conditions [top]

For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.

SEDBASE: SIDE EFFECTS OF DRUGS: ELSEVIER REPRESENTS THAT SEDBASE: SIDE EFFECTS OF DRUGS, THE DATABASE PROVIDED HEREUNDER, WAS FORMULATED WITH A REASONABLE STANDARD OF CARE AND IN CONFORMANCE TO PROFESSIONAL STANDARDS IN THE FIELD. EXCEPT WITH RESPECT TO THE FOREGOING AND AS OTHERWISE SPECIFICALLY PROVIDED IN THIS AGREEMENT, ELSEVIER MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THIS DATABASE AND SPECIFICALLY DISCLAIMS ALL SUCH WARRANTIES AND REPRESENTATIONS.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnoses and drug dosages should be made.

ELSEVIER DOES NOT WARRANT THE SCIENTIFIC ACCURACY OR COMPLETENESS OF THE INFORMATION CONTAINED IN SEDBASE NOR DOES IT WARRANT THE SUITABILITY OF THIS INFORMATION FOR ANY PARTICULAR USE OR APPLICATION, INCLUDING, BUT NOT LIMITED TO IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS OR SUITABILITY FOR A PARTICULAR PURPOSE CONSEQUENTLY, ELSEVIER CANNOT BE HELD RESPONSIBLE FOR ANY DAMAGES ARISING FROM THE USE OF SEDBASE.


Dialog Standard Terms & Conditions apply.


SAMPLE RECORD [top]

    File  70:SEDBASE  1996/Jan Q1 
    (c) 1996 Elsevier B.V. 
     
    00728276  SEDBASE No.: 00109766   Line Count: 12 
  NR=   Number of Cited Reference: 2 
  /DE, /NA, NA=    Drug Name: LITHIUM 
  DC=   Drug Classification: 03 
  /DE, SY=   Synonym(s) for Drug Name: LITHIUM SALT;  LITHIUM COMPOUND; 
        LITHIUM CHLORIDE;  LITHIUM CITRATE;  LITHIUM CARBONATE 
  /DE, /IN, IN=   Interacting Drug Name: METHYLDOPA 
  IC=   Interacting Drug Classification Code: 21.04 
     Synonym(s) for Interacting Drug: alpha methyldopa; 
        (-)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropionic acid; 
        3,4-dihydroxy-alpha-methylphenylalanine; 
        (-)-3-(3,4-dihydroxyphenyl)-2-methylalanine;  MK-351;  aldomet 
        ;  aldometil; 
        2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropionic acid; 
        3-(3,4-dihydroxyphenyl)-2-methylalanine;  dopamet;  dopegyt; 
        hyperpax;  medomet;  mulfasin;  presinol;  sedometil; 
        sembrina;  hydromet 
     
  /DE, /EN, EN=   Effect Interaction Name: SPEECH SLURRING 
  EC=   Effect Classification Code: 14.03 
  /DE, /EN, EN=   Synonym(s) for Effect Name: DYSARTHRIA 
  /DE, /FI, FI=   FACTORS OF INFLUENCE: RENOVASCULAR HYPERTENSION 
     OTHER FACTORS: 
  SP=      Incidence mentioned 
     
  SO=   Meyler's Side Effect of Drugs SED text,    03.08 
  /TX      Problems can arise in antihypertensive treatment. 
     One  patient  on  lithium developed ataxia and slurred speech 2-3 
     weeks  after  starting methyldopa. Serum lithium was 1.5 mmol/l 2 
     days after admission, and mild lithium intoxication might account 
     for  the  symptoms.  It is not clear whether the intoxication was 
     precipitated by methyldopa or by other factors in the presence of 
     hypertensive  renal  insufficiency.  It  has  been suggested that 
     lithium patients needing antihypertensive drugs should preferably 
     be  given  a beta-blocker, therapy with thiazides is inadvisable; 
     amiloride may be less dangerous.  Interaction with ACE inhibitors 
     (inhibitors of the enzyme that converts angiotensin I to 
     angiotensin II) such as enalapril, captopril, and lisinopril may 
     lead to impaired glomerular filtration and elevation of serum 
     creatine and serum lithium. 
     
     CITED REFERENCE(S): 
  /TI      Title: Adverse interaction of lithium carbonate and 
           methyldopa. 
  AU=      Author: O Regan J B. 
  CS=      Author Address: 803 CN Towers, Saskatoon; Canada. 
  JN=, PY=      Cited Works: CAN-MED-ASS-J  1976, 115/5 (385-386). 
        Cited Publication Year: 1976 
  LA=      Language: English 
     
  /TI      Title: The problem of antihypertensive treatment in lithium 
           patients. 
  AU=      Author: Schwarcz G. 
  CS=      Author Address: St. Elizabeth Hosp., Washington, DC; USA. 
  JN=, PY=      Cited Works: COMPR-PSYCHIATRY  1982, 23/1 (50-54). 
        Cited Publication Year: 1982 
  LA=      Language: English 
        Country of Author: US. 
  /AB      EMBASE  Abstract:  Given  a  thorough  understanding  of their 
     pharmacology  and  of  renal physiology, diuretics can usually be 
     safely used in conjunction with lithium. Where possible, however, 
     beta-blockers should be first-line drugs in treating hypertension 
     since  they  have  no  electrolyte  effects.  Alternate drugs and 
     checking  for  noncompliance  can  be  useful in the hypertensive 
     patient   in   whom   first-line   drugs   are   ineffective   or 
     contraindicated.  Meyler's Side Effects of Drugs SED text, 03.08 


BASIC INDEX [top]

SEARCH
SUFFIX		 DISPLAY
CODE		 FIELD NAME
 INDEXING
 SELECT EXAMPLES
None None All Basic Index Fields Word S LITHIUM(W)CARBONATE
/AB AB Abstract Word S BETA(W)BLOCKER?/AB
/DE DE Descriptor1,2 Word
& Phrase		 S DYSARTHRIA/DE
S RENOVASCULAR HYPERTENSION/DE
/EN EN Effect Interaction Name3 Word
& Phrase		 S SPEECH/EN
S SPEECH SLURRING/EN
/FI FI Factors of Influence3 Word
& Phrase		 S HYPERTENSION/FI
S RENAL INSUFFICIENCY/FI
/IN IN Interacting Drug Name3,4 Word
& Phrase		 S METHYLDOPA/IN
S SODIUM BICARBONATE/IN
/NA NA Drug Name4 Word
& Phrase		 S LITHIUM/NA
S LOXAPINE SUCCINATE/NA
/TI TI Title of Cited Reference Word S LITHIUM(W)CARBONATE/TI
/TX TX Text Word S SERUM(W)LITHIUM/TX

1 Also /DF.

2 Descriptor includes Drug Name, Interacting Drug Name, Effect Interaction Name, Factors of Influence, Synonyms (for Effect Name).

3 Also searchable using /DE.

4 Searchable in the Basic Index and in the Additional Indexes.


ADDITIONAL INDEXES [top]

SEARCH
PREFIX		 DISPLAY
CODE		 FIELD NAME
 INDEXING
 SELECT EXAMPLES
None AN DIALOG Accession Number
AN= AN SEDBASE Accession Number Phrase S AN=00109766
AU= AU Author Name Phrase S AU=O REGAN J B.
CS= CS Corporate Source Word S CS=(CN(W)TOWERS AND SASKATOON)
DC= DC Drug Classification Code Phrase S DC=03
EC= EC Effect Classification Code Phrase S EC=14.03
ED= ED Editor of Cited Book Phrase S ED=BOURNE P
EN= EN Effect Interaction Name4 Phrase S EN=SPEECH SLURRING
FI= FI Factors of Influence4 Phrase S FI=RENAL INSUFFICIENCY
IC= IC Interacting Drug Classification Code Phrase S IC=21.04
IN= IN Interacting Drug Name3,4 Phrase S IN=METHYLDOPA
JN= JN Journal Name Phrase S JN=CAN-MED-ASS-J
LA= LA Language Phrase S LA=ENGLISH
None LC Number of Lines in Fulltext
NA= NA Drug Name4 Phrase S NA=LITHIUM
NR= NR Number of Cited References Phrase S NR=2
PU= PU Publisher Phrase S PU=ELSEVIER, BIOMEDICAL PRESS?
PY= PY Publication Year Phrase S PY=1982
SO= SO Source Information Phrase S SO=MEYLER'S SIDE EFFECT OF DRUGS?
SP= SP Treatment, Incidence, Mechanism Phrase S SP=INCIDENCE MENTIONED
ST= ST Status Phrase S ST=NEW RECORD
SY= SY Synonyms for Drug Name and Interacting Drug Name Phrase S SY=LITHIUM SALT?
UD= None Update Phrase S UD=9999
XR= XR Cross Reference Field Phrase S XR=MAPROTILINE


LIMIT [top]

Sets and terms may be limited by Basic Index suffixes, i.e., /AB, /DE, /DF, /EN, /FI, /IN, /NA, /TI, /TX (e.g., S S6/TX).
SUFFIX FIELD NAME EXAMPLES
/INTERACT Interacting Drug Name Present S S1/INTERACT
/REF Cited References Present S S3/REF
/YYYY Publication Year S S2/1993:1994


SORT [top]

SORTABLE FIELDS EXAMPLES
DC, EC, EN, IC, IN, NA SORT S1/ALL/NA
SORT S2/ALL/DC


RANK [top]

RANK FIELDS EXAMPLES
All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. Other RANK codes include: DE RANK AU S3


MAP [top]

MAP FIELDS EXAMPLES
NA, SY MAP SY TEMP S1


USER-DEFINED FORMAT OPTIONS [top]

User-defined formats may be specified using the display codes indicated in the Search Options tables. TYPE S3/NA,SY/1-5
PRINT S1/TI,AB/ALL


PREDEFINED FORMAT OPTIONS [top]

NO.
 DIALOGWEB
FORMAT		 RECORD CONTENT
1 -- DIALOG and SEDBASE Accession Numbers
2 -- Full Record except Text, EMBASE Abstract, and Cited Reference
3 Medium Drug Name, Interacting Drug Name, Effect Interaction Name, Synonyms for Effect Name, Synonyms for Drug Name, Synonyms for Interactions
4 -- Full Record with Tagged Fields
5 Long Full Record
6 Free Drug Name, Number of Cited References, Effect Name, and Interacting Drug Name
7 -- Full Record except Indexing
8 Short Drug Name, Number of Cited References, Effect Name, Interacting Drug Name, and Indexing
9 Full Full Record
K -- KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats


DIRECT RECORD ACCESS [top]

FIELD NAME EXAMPLES
DIALOG Accession Number TYPE 0001685/5
DISPLAY 0001443/9
PRINT 0001562/3


Rates [top]

Rates For File: SEDBASE: Side Effects of Drugs [70]
Cost per DialUnit:                 $9.60
Cost per minute:                   $1.60
Rank Elements                      $0.00

Format    Types   Prints
     1    $0.00    $0.00
     2    $5.40    $5.40
     3    $5.40    $5.40
     4   $10.05   $10.05
     5   $10.05   $10.05
     6    $0.00    $0.00
     7   $10.05   $10.05
     8    $0.00    $0.00
     9   $10.05   $10.05
KWIC95    $1.05       NA
KWIC96    $1.05       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
[top]


All contents Copyright © Thomson Reuters. All rights reserved.
If you have any questions about, problems with, or corrections for our Web site,
please contact Customer Service for assistance.